{"title":"Convalescent plasma therapy for managing infectious diseases: a narrative review","authors":"M. Franchini","doi":"10.21037/AOB-2020-CP-03","DOIUrl":null,"url":null,"abstract":"The coronavirus disease 2019 (COVID-19) pandemic in 2020 is one of the worst catastrophic events in human history. A number of therapeutic modalities have been utilized in order to fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), although the majority of them failed to demonstrate a beneficial clinical effect. Among the anti-COVID-19 agents being investigated, the convalescent plasma collected from recovered donors has gained a growing interest. Convalescent plasma has been employed for over a hundred years to treat severe acute viral infections when a vaccine or a specific antiviral treatment was not yet available. In this narrative review, we summarize the literature data on the use of convalescent plasma during previous viral outbreaks and pandemics, including influenza viruses, coronaviruses other than SARS-CoV-2 and Ebola virus. A literature search, using the Medline and PubMed electronic database, was performed to retrieve publications on the use of convalescent plasma in previous viral epidemics. In conclusion, the available literature data suggest the safety profile of convalescent plasma and its potential benefit in treating emerging viral infectious diseases. In addition, these data retrieved from previous viral epidemics provide a solid rationale for the employment of plasma from convalescent donors also in COVID-19 patients.Copyright © 2021 AME Publishing Company. All rights reserved.","PeriodicalId":72211,"journal":{"name":"Annals of blood","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of blood","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/AOB-2020-CP-03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
康复血浆疗法治疗传染病:叙述性综述
2020年的2019冠状病毒病(新冠肺炎)大流行是人类历史上最严重的灾难性事件之一。为了对抗严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2),已经使用了许多治疗模式,尽管其中大多数未能证明有益的临床效果。在正在调查的抗COVID-19药物中,从康复捐赠者那里收集的恢复期血浆越来越引起人们的兴趣。在尚未获得疫苗或特定抗病毒治疗的情况下,恢复期血浆已被用于治疗严重急性病毒感染超过一百年。在这篇叙述性综述中,我们总结了在以前的病毒爆发和大流行期间使用恢复期血浆的文献数据,包括流感病毒、除严重急性呼吸系统综合征冠状病毒2型和埃博拉病毒以外的冠状病毒。使用Medline和PubMed电子数据库进行文献检索,以检索关于在以前的病毒流行中使用恢复期血浆的出版物。总之,现有的文献数据表明了恢复期血浆的安全性及其在治疗新发病毒性传染病方面的潜在益处。此外,从以前的病毒流行中检索到的这些数据为新冠肺炎患者使用恢复期捐献者的血浆提供了坚实的依据。版权所有©2021 AME出版公司。保留所有权利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。